Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.62 |
| ▸ | ITGAV | P06756 | 20/20 | 0.62 |
| ▸ | ITGA2B | P08514 | 18/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6829353 | 0.92 | ITGB3 (0.63) | ITGB3ITGAVITGA2B | |
| SCHEMBL6832543 | 0.92 | ITGB3 (0.62) | ITGB3ITGAVITGA2B | |
| SCHEMBL6831991 | 0.91 | ITGB3 (0.62) | ITGB3ITGAVITGA2B | |
| SCHEMBL6829400 | 0.91 | ITGB3 (0.63) | ITGB3ITGAVITGA2B | |
| SCHEMBL6829399 | 0.90 | ITGB3 (0.50) | ITGB3ITGAVITGA2B | |
| SCHEMBL6497993 | 0.90 | ITGB3 (0.76) | ITGB3ITGAVITGA2B | |
| SCHEMBL6832018 | 0.84 | ITGB3 (0.55) | ITGB3ITGAVITGA2B | |
| SCHEMBL6832434 | 0.81 | ITGAV (0.45) | ITGB3ITGAVITGA2B | |
| SCHEMBL6869337 | 0.81 | ITGB3 (0.51) | ITGB3ITGAVITGA2B | |
| SCHEMBL4838464 | 0.81 | ITGB3 (0.63) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747148-B2 | FOR THERPY AND PROPHYLAXIS OF OSTEOPOROSIS, HYPERCALCEMIA, OR OSTEOPENIA, INFLAMMATION, CARDIOVASCULAR DISORDERS, RESTENOSIS, ARTERIOSCLEROSIS, NEPHROPATHIES OR RETINOPATHIES | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (DE) | 2004-06-08 | — | — | US | disclosed |
| US-20020065271-A1 | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion | PEYMAN ANUSCHIRWAN (DE) | 2002-05-30 | — | — | US | disclosed |
| US-6313119-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | ADVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-11-06 | — | — | US | disclosed |
| EP-1049677-A1 | NOVEL SULFONAMIDE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS INHIBITORS OF CELL ADHESION | Aventis Pharma Deutschland GmbH (DE) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037621-A1 | NOVEL SULFONAMIDE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065271-A1 | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion | SOST, SELPLG, BST2 | ITGB3 84/4885ITGAV 159/4885ITGA2B 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.